Instrument Inactif

Communiqués Therapix Biosciences Ltd TEL AVIV STOCK EXCHANGE

Actions

TRPX

IL0010951403

Cours en clôture TEL AVIV STOCK EXCHANGE Autres places de cotation
- ^ILS	-

03/06	SciSparc Ltd. s'assure un avantage stratégique avec la délivrance d'un brevet européen	CI
01/04	SciSparc Ltd. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

SciSparc : Report Of Foreign Private Issuer Form 6 K	14/06	PU
SciSparc Secures Strategic Advantage with Grant of European Patent	31/05	GL
SciSparc to Acquire AutoMax	11/04	GL
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research	21/03	GL
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada	18/03	GL
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada	18/03	AQ
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial	14/03	GL
SciSparc : MitoCareX Update - Form 6-K	13/03	PU
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure	12/03	GL
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure	12/03	AQ
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder	08/03	GL
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder	08/03	AQ
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe	07/03	GL
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe	07/03	AQ
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology	06/03	GL
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing	29/02	GL
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing	29/02	AQ
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds	27/02	GL
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds	27/02	AQ
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classical Psychedelic-Based Compounds	21/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Therapix Biosciences Ltd TEL AVIV STOCK EXCHANGE

Actions

TRPX

IL0010951403

Communiqués

Filtres